Display options
Cite
Nazha A, Bueso-Ramos C, Estey E, et al. The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia. Front Oncol. 2013;3:218doi: 10.3389/fonc.2013.00218.
Nazha, A., Bueso-Ramos, C., Estey, E., Faderl, S., O'Brien, S., Fernandez, M. H., Nguyen, M., Koller, C., Freireich, E., Beran, M., Pierce, S., Keating, M., Cortes, J., Kantarjian, H., & Ravandi, F. (2013). The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia. Frontiers in oncology, 3218. https://doi.org/10.3389/fonc.2013.00218
Nazha, Aziz, et al. "The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia." Frontiers in oncology vol. 3 (2013): 218. doi: https://doi.org/10.3389/fonc.2013.00218
Nazha A, Bueso-Ramos C, Estey E, Faderl S, O'Brien S, Fernandez MH, Nguyen M, Koller C, Freireich E, Beran M, Pierce S, Keating M, Cortes J, Kantarjian H, Ravandi F. The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia. Front Oncol. 2013 Sep 06;3:218. doi: 10.3389/fonc.2013.00218. eCollection 2013. PMID: 24032106; PMCID: PMC3764477.
Copy Download .nbib Format: NLM
Share it on

Front Oncol. 2013 Sep 06;3:218. doi: 10.3389/fonc.2013.00218. eCollection 2013.

The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia.

Frontiers in oncology

Aziz Nazha, Carlos Bueso-Ramos, Eli Estey, Stefan Faderl, Susan O'Brien, Michael H Fernandez, Martin Nguyen, Charles Koller, Emil Freireich, Miloslav Beran, Sherry Pierce, Michael Keating, Jorge Cortes, Hagop Kantarjian, Farhad Ravandi

Affiliations

  1. Department of Leukemia, University of Texas , Austin, TX , USA.

PMID: 24032106 PMCID: PMC3764477 DOI: 10.3389/fonc.2013.00218

Abstract

BACKGROUND: Previous studies have suggested that NPM1 mutations may be a marker for response to all-trans retinoic acid (ATRA) given as an adjunct to intensive chemotherapy in older patients with acute myeloid leukemia (AML).

PATIENTS AND METHODS: We examined the impact of the addition of ATRA among patients with diploid cytogenetics treated on a randomized phase II study of fludarabine + cytarabine + idarubicine ± G-CSF ± ATRA with available data on their NPM1 mutation status. Between September 1995 and November 1997, 215 patients were enrolled in the study. Among them, 70 patients had diploid cytogenetic and are the subjects of this analysis.

RESULTS: The median age of the 70 patients was 66 years (range 23-87). Twenty (29%) of patients had NPM1 mutations. Among them 7 (35%) did and 13 (65%) did not receive ATRA in combination with chemotherapy. Complete remission (CR) was achieved in 71% of patients treated with ATRA as compared to 69% without ATRA (P = 0.62). With median follow-up of 12.5 years, the overall survival (OS), event-free survival (EFS), and relapse-free survival (RFS) were similar among patients who received ATRA compared to no ATRA regardless of NPM1 mutation status.

CONCLUSION: The addition of ATRA to intensive chemotherapy did not affect the overall outcome of patients with AML regardless of NPM1 mutation status.

Keywords: AML; ATRA; NPM1; chemotherapy; elderly

References

  1. J Clin Oncol. 2010 Feb 1;28(4):596-604 - PubMed
  2. Blood. 2006 Jun 15;107(12):4614-22 - PubMed
  3. Leukemia. 1995 Jul;9(7):1121-5 - PubMed
  4. Blood. 1998 Sep 1;92(5):1768-75 - PubMed
  5. Blood. 2006 Sep 15;108(6):1999-2005 - PubMed
  6. Haematologica. 2009 Jan;94(1):54-60 - PubMed
  7. Blood. 2006 May 15;107(10):4011-20 - PubMed
  8. Blood. 2010 Feb 4;115(5):948-56 - PubMed
  9. Cancer. 2007 Mar 15;109(6):1114-24 - PubMed
  10. N Engl J Med. 1999 Sep 30;341(14):1051-62 - PubMed
  11. Blood. 1997 Dec 1;90(11):4578-87 - PubMed
  12. Blood. 2007 Feb 1;109(3):874-85 - PubMed
  13. Leukemia. 1995 Oct;9(10):1667-73 - PubMed
  14. Blood. 2009 Oct 1;114(14):3024-32 - PubMed
  15. Blood. 2008 Mar 1;111(5):2776-84 - PubMed
  16. Blood. 1995 Sep 1;86(5):1903-10 - PubMed
  17. Blood. 1999 Apr 15;93(8):2478-84 - PubMed
  18. J Clin Oncol. 2009 Feb 1;27(4):504-10 - PubMed
  19. Cancer. 2009 Oct 15;115(20):4737-44 - PubMed
  20. N Engl J Med. 2005 Jan 20;352(3):254-66 - PubMed

Publication Types

Grant support